These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 7969745)

  • 1. Cortical and subcortical neuropeptides in Alzheimer's disease.
    Auchus AP; Green RC; Nemeroff CB
    Neurobiol Aging; 1994; 15(4):589-95. PubMed ID: 7969745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuropeptide changes in cortical and deep gray structures in Alzheimer's disease.
    Roeske LC; Auchus AP
    Rev Neurosci; 1995; 6(4):317-28. PubMed ID: 8845972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cortical somatostatin, neuropeptide Y, and NADPH diaphorase neurons: normal anatomy and alterations in Alzheimer's disease.
    Kowall NW; Beal MF
    Ann Neurol; 1988 Feb; 23(2):105-14. PubMed ID: 2897822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galanin hyperinnervates surviving neurons of the human basal nucleus of Meynert in dementias of Alzheimer's and Parkinson's disease: a hypothesis for the role of galanin in accentuating cholinergic dysfunction in dementia.
    Chan-Palay V
    J Comp Neurol; 1988 Jul; 273(4):543-57. PubMed ID: 2463283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropeptides in neurological disease.
    Beal MF; Martin JB
    Ann Neurol; 1986 Nov; 20(5):547-65. PubMed ID: 2947536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer's disease: neurofibrillary tangles in nuclei that project to the cerebral cortex.
    German DC; White CL; Sparkman DR
    Neuroscience; 1987 May; 21(2):305-12. PubMed ID: 3302759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholecystokinin and somatostatin in Alzheimer's disease postmortem cerebral cortex.
    Mazurek MF; Beal MF
    Neurology; 1991 May; 41(5):716-9. PubMed ID: 1674117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galanin immunoreactivity is increased in the nucleus basalis of Meynert in Alzheimer's disease.
    Beal MF; MacGarvey U; Swartz KJ
    Ann Neurol; 1990 Aug; 28(2):157-61. PubMed ID: 1699471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurotransmitter changes in Alzheimer's disease: implications to diagnostics and therapy.
    Reinikainen KJ; Soininen H; Riekkinen PJ
    J Neurosci Res; 1990 Dec; 27(4):576-86. PubMed ID: 1981917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropeptides in Alzheimer's disease: a review and morphological results.
    Bouras C; de St Hilaire-Kafi S; Constantinidis J
    Prog Neuropsychopharmacol Biol Psychiatry; 1986; 10(3-5):271-86. PubMed ID: 2432629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropeptides in Alzheimer's disease: a postmortem study.
    Nemeroff CB; Kizer JS; Reynolds GP; Bissette G
    Regul Pept; 1989 Apr; 25(1):123-30. PubMed ID: 2566190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of neurotransmitter-specific and neuropeptide-specific neuronal cell types present in the dorsal cortex in turtles with those present in the isocortex in mammals: implications for the evolution of isocortex.
    Reiner A
    Brain Behav Evol; 1991; 38(2-3):53-91. PubMed ID: 1683805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional interactions of galanin and acetylcholine: relevance to memory and Alzheimer's disease.
    Crawley JN
    Behav Brain Res; 1993 Nov; 57(2):133-41. PubMed ID: 7509609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of Alzheimer's disease-related cytoskeletal changes in the basal nucleus of Meynert.
    Sassin I; Schultz C; Thal DR; Rüb U; Arai K; Braak E; Braak H
    Acta Neuropathol; 2000 Sep; 100(3):259-69. PubMed ID: 10965795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Degeneration of the basalocortical pathway from the cortex induces a functional increase in galaninergic markers in the nucleus basalis magnocellularis of the rat.
    Barbelivien A; Vaussy C; Marchalant Y; Maubert E; Bertrand N; Beley A; Roussel S; Mackenzie ET; Dauphin F
    J Cereb Blood Flow Metab; 2004 Nov; 24(11):1255-66. PubMed ID: 15545921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropeptide abnormalities in patients with early Alzheimer disease.
    Davis KL; Mohs RC; Marin DB; Purohit DP; Perl DP; Lantz M; Austin G; Haroutunian V
    Arch Gen Psychiatry; 1999 Nov; 56(11):981-7. PubMed ID: 10565496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropeptides in Alzheimer's disease.
    Beal MF; Kowall NW; Mazurek MF
    J Neural Transm Suppl; 1987; 24():163-74. PubMed ID: 2445913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pattern of brain destruction in Parkinson's and Alzheimer's diseases.
    Braak H; Braak E; Yilmazer D; de Vos RA; Jansen EN; Bohl J
    J Neural Transm (Vienna); 1996; 103(4):455-90. PubMed ID: 9617789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell loss in the nucleus basalis is related to regional cortical atrophy in Alzheimer's disease.
    Cullen KM; Halliday GM; Double KL; Brooks WS; Creasey H; Broe GA
    Neuroscience; 1997 Jun; 78(3):641-52. PubMed ID: 9153647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuropeptides and Alzheimer's disease.
    Gottfries CG; Frederiksen SO; Heilig M
    Eur Neuropsychopharmacol; 1995 Dec; 5(4):491-500. PubMed ID: 8998402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.